Findings from an in situ single-cell analysis suggest that, while mutated PIK3CA and HER2 gene amplifications occurs individually in HER2-positive breast cancer, following chemotherapy, the cell population containing both alterations was enriched in patients with resistant disease [24]. Here, PIK3CA is linked to breast cancer.